CCRC Staff (left to right): Rogelio Almario, M.S., April Canty, RN, M.S.N., Josefina Wong, RN, B.S.N., Barbara Gale, M.A., Christopher Kain, RN, M.S.N.
The CTSC Clinical Research Center (CCRC) at UC Davis Health received the Patient Safety Innovation Award for supporting the pioneering research into a #COVID-19 #pfizer #vaccine. Under the leadership of Daniel Nishijima, M.D., M.A.S., and Christopher Kain, RN, M.S.N., the team serves as the clinical component of the UC Davis Clinical and Translational Science Center (CTSC), funded by an NIH grant through the National Center for Advancing Translational Science (NCATS). The CCRC offers carefully monitored clinical resources necessary for patient-oriented research. Resources include unique equipment and protocol administration tools, as well as highly experienced staff trained in human subjects’ protection, good clinical practices, protocol implementation, and compliance, thus ensuring the quality of data collected and the integrity of the research.
The CCRC worked tirelessly to ensure the COVID vaccine trials were run safely with each participant. They dosed and monitored 227 participants in the Phase III clinical trial – this entailed two doses per person, plus a second two doses for half the subjects to administer the active drug to the placebo cohort. In addition, the CCRC has begun coordinating the #Novavax vaccine trial in addition to the numerous other COVID and non-COVID trials that are managed by the team.
Toby Marsh, chief nursing and patient care services officer at UC Davis Medical Center, presented the award. Mr. Marsh expressed his appreciation to the CCRC for providing high-quality vaccine trial data through innovation to aid in developing an efficacious COVID-19 vaccine.
- Clinical Research
- Clinical Trials
- University of California Davis, CTSA Program Hub
University Of California Davis
CTSA Program In Action Goals
Goal 4: Innovate Processes to Increase the Quality and Efficiency of Translational Research, Particularly of Multisite Trials